**FOI Ref: 6575**

**Category(ies): Clinical - Drugs**

**Subject: Patients Treatments (Revolade, Nplate, Doptelet, Tavlesse)**

**Date Received: 23/08/2022**

|  |  |
| --- | --- |
| **Your request:** | **Our response:** |
| 1. How many patients has your trust treated (for any disease) in the last 6 months (or the latest 6 months data you have available) with the treatments listed below:  * Revolade (eltrombopag) * Nplate (romiplostim) * Doptelet (avatrombopag) * Tavlesse (fostamatinib) | We only keep eltrombopag and romiplostim as per pharmacy colleagues.  6 separate patients treated with one of or both Romiplostim and Eltrombopag between 01/03/2022 and 31/08/2022. |
| 1. In the last 6 months (or the latest 6 months data you have available), how many patients has your trust treated for immune thrombocytopenia (ITP)? | 32 individual patients treated that have a diagnosis of immune thrombocytopenia (D693) coded on their inpatient spell that were discharged between 01/03/2022 and 31/08/2022. |
| 1. Of the patients treated for immune thrombocytopenia (ITP) in the last 6 months (or the latest 6 months data you have available), how many were treated with:  * rituximab * mycophenolate mofetil * surgery (splenectomy) | * Rituximab - 0 * Mycophenolate mofetil – 1 * Surgery (splenectomy) - 0 Clinical coding have informed me we don’t perform this procedure. |
| 1. Does your trust participate in any ongoing clinical trials for immune thrombocytopenia (ITP)? If so, can you please provide the name of each trial along with the number of patients taking part? | No TRFT (The Rotherham NHS Foundation Trust) does not participate in clinical trials for for immune thrombocytopenia (ITP) |